Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study

Documenti analoghi

• Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario
  di: Antonio Pinto, et al.
  Pubblicazione: (2024)
• 409 | EARLY IDENTIFICATION OF CAR T‐CELL THERAPY NON‐RESPONDERS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA USING FDG‐PET QUANTITATIVE PARAMETERS
  di: C. Pellegrini, et al.
  Pubblicazione: (2025)
• Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus‐based position paper from an ad hoc expert panel
  di: Francesca Romana Mauro, et al.
  Pubblicazione: (2024)
• A Real‐Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B ‐Cell Lymphoma
  di: Gabriele Gugliotta, et al.
  Pubblicazione: (2026)
• Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
  di: Pier Luigi Zinzani, et al.
  Pubblicazione: (2025)